
    
      The study is both retrsopective and prospective to collect local real life data on patients
      under routine treatment.

      The observation periods starts on January 2014. Patients who initiated a treatment by
      Aflibercept between the 1st of january 2014 and the 31 December 2015 will be enrolled.
    
  